Agile therapeutics inc (AGRX)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-21,820

-18,606

-16,395

-15,755

-17,615

-19,779

-22,209

-25,520

-27,621

-28,304

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-29,115

-

0

0

0

-

-

-

-

Net loss (income)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

17

18

19

21

22

23

25

24

24

23

21

21

20

19

18

17

17

18

18

16

14

12

0

0

0

Amortization

147

145

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Noncash stock bonus

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

80

0

0

0

Noncash stock bonus

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Noncash stock based compensation

1,893

1,762

2,150

2,493

3,001

3,630

3,751

3,997

3,935

3,651

3,545

3,519

3,549

3,425

3,443

3,248

3,031

2,965

2,536

2,171

1,797

1,381

0

0

0

Loss on extinguishment of debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-1,036

0

0

0

-

-

-

-

Noncash interest

-

-

-

-

-

282

514

569

620

667

707

962

960

946

932

689

689

590

463

338

224

185

0

0

0

Noncash interest

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

-29

-90

-70

-41

-143

-148

-206

-150

-234

-13

-80

-184

110

-114

-95

-234

-348

0

0

0

Changes in operating assets and liabilities:
Prepaid expenses and other assets

294

233

585

-22

-255

-155

-431

-325

-1,892

-2,006

-1,933

-1,548

-509

-922

0

0

0

-

-

-

-

2,335

0

0

0

Prepaid expenses and other current assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Accounts payable and accrued expenses

1,501

1,377

-654

-1,123

-1,923

-1,177

-1,991

-1,874

-3,077

-2,460

-463

-100

1,481

362

-2,306

-606

-148

1,347

3,383

2,179

3,613

2,599

0

0

0

Lease liability

157

152

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-18,612

-15,689

-15,555

-14,326

-16,140

-16,895

-19,569

-22,549

-24,268

-24,560

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-26,571

-

-25,921

-26,483

-21,080

-14,503

0

0

0

Acquisition of property and equipment

0

-

-

-

-

318

860

1,179

1,584

1,313

777

461

34

31

27

35

103

290

341

364

283

96

0

0

0

Net cash used in investing activities

0

-

-

-

-

-318

-860

-1,179

-1,584

-1,313

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities:
Proceeds from issuance of common stock in private placement, net of offering costs

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from sales or issuance of common stock, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

37,528

0

0

0

-

0

0

0

-

-

-

-

Proceeds from issuance of long-term debt

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-103

-

-341

-364

-283

-96

0

0

0

Cash paid for offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Proceeds from issuance term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

16,265

0

0

0

-

-

-

-

Repayment of term loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

15,784

0

0

0

-

-

-

-

Principal payments of long-term debt

-

-

-

-

-

10,888

6,526

6,379

6,235

5,612

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Debt financing costs paid

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

423

0

0

0

-

-

-

-

Proceeds from exercise of stock options

0

-

-

-

-

-

-

-

-

-

-

-

-

334

390

608

757

593

0

0

0

-

-

-

-

Net cash provided by financing activities

101,239

42,415

17,029

2,449

-602

-10,888

-6,451

12,255

12,452

13,075

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net increase in cash and cash equivalents

82,365

26,628

1,444

-11,879

-16,784

-28,101

-26,880

-11,473

-13,400

-12,798

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Interest paid

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,510

-

1,443

1,409

1,374

1,380

0

0

0

Supplemental disclosure of noncash financing activities
Warrants issued in connection with long-term debt

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by (used in) financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

38,304

-

19,987

19,760

72,219

52,661

0

0

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,630

-

-6,276

-7,087

50,854

38,062

0

0

0

Supplemental cash flow information
Interest paid

0

-

-

-

-

1,370

897

1,031

1,166

1,295

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Fair value of common stock warrants issued

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,184

0

0

0

-

-

-

-

At-the-market sales
Proceeds from sales or issuance of common stock, net of offering costs

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Public offering
Proceeds from sales or issuance of common stock, net of offering costs

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-